EcoDrugPlus

Tubulin Beta Class I

Ensembl ID : ENSXETG00000024084
Gene Symbol: TUBB
19 Enzyme and pathways 5 View Cross-references
355 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tumor Protein P53

Ensembl ID : ENSXETG00000025055
Gene Symbol: TP53
5 View Cross-references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Type 2/nmi Gonadotropin-Releasing Hormone Receptor

Ensembl ID : ENSXETG00000038283
Gene Symbol: GNRHR2/NMI
4 View Cross-references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosinase

Ensembl ID : ENSXETG00000011738
Gene Symbol: TYR
3 Enzyme and pathways 5 View Cross-references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine Hydroxylase

Ensembl ID : ENSXETG00000014030
Gene Symbol: TH
4 Enzyme and pathways 5 View Cross-references
187 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine Kinase 2

Ensembl ID : ENSXETG00000011623
Gene Symbol: TYK2
14 Enzyme and pathways 5 View Cross-references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosine-Protein Kinase Styk1-Like

Ensembl ID : ENSXETG00000042884
Gene Symbol: LOC116412185
4 View Cross-references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Uncharacterized Xb5944457

Ensembl ID : ENSXETG00000012105
Gene Symbol: XB5944457
9 Enzyme and pathways 5 View Cross-references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Utrophin

Ensembl ID : ENSXETG00000022290
Gene Symbol: UTRN
5 View Cross-references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

V-Akt Murine Thymoma Viral Oncogene Homolog 1

Ensembl ID : ENSXETG00000008603
Gene Symbol: AKT1
5 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSXETG00000016986
Gene Symbol: AKT2
5 View Cross-references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Vascular Endothelial Growth Factor A

Ensembl ID : ENSXETG00000016375
Gene Symbol: VEGFA
11 Enzyme and pathways 5 View Cross-references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).